Solid Biosciences Inc. (SLDB) research
Solid Biosciences Inc.- Sector
- Biotechnology
- Last price
- $7.48
- As of
Solid Biosciences Inc. (SLDB): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
As of . Source: SEC EDGAR filings for SLDB. Method and limitations.
Share the SLDB intelligence card
See SLDB live in the terminal
Track SLDB's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live SLDB terminal, freeActive signals for SLDB
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 78% of SLDB (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 74% of SLDB (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +2242% to SLDB (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +74% to SLDB (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 78% of SLDB (2026Q2)
FREE, NO ACCOUNT
Every signal on SLDB, as it fires
You are seeing 5 of 18 signals recorded on SLDB since 2026-05-17.
The five above all landed on 2026-09-06. The other 13 were recorded on 3 other days. 14 of the 18 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SLDB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 83422E204 · 2026Q2 | $28.1M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 83422E204 · 2026Q2 | $4.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 83422E204 · 2026Q2 | $2.2M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 83422E204 · 2026Q2 | $820K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 83422E204 · 2026Q2 | $606K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SLDB
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
SLDB against its peers
SLDB's return on equity of -96.8% ranks in the 11th percentile of 21 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | SLDB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 67.5M | n/a | 11 |
| Operating margin | n/a | -187.2% | n/a | 11 |
| Net margin | n/a | -164.4% | n/a | 11 |
| Return on equity | -96.8% | -37.3% | 11 | 21 |
Peers (22): SGP, LXRX, CADL, ABUS, JANX, SANA, IMMX, CLYM, AVTX, TBPH, ARDX, KURA, SVRA, GLUE, MLTX, CRVS, RIGL, OLMA, WVE, JBIO, GERN, FDMT. Left out: HELP (period gap), IVA (period gap), ANL (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (SLDB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SLDB signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SLDBand get the insider, 13F, options, and confluence read in one view.